Nimbus Therapeutics has appointed Abbas Kazimi as Chief Executive Officer and a member of its Board of Directors, effective immediately. Kazimi succeeds Jeb Keiper as part of a planned leadership transition. Kazimi has been with Nimbus since 2014 and most recently served as Chief Business Officer, where he played a key role in securing more than $7 billion in capital through strategic transactions, including the 2022 TYK2 deal with Takeda. He also expanded the company’s computational drug discovery platform through key technology partnerships. Kazimi expressed enthusiasm about leading Nimbus during a critical phase, highlighting the company's growing pipeline, including its WRN and SIK inhibitor programs and collaboration with Lilly.
Nimbus Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule medicines targeting difficult-to-drug proteins associated with a variety of diseases. Kazimi said, "Our robust pipeline, anchored by promising programs like our WRN and SIK inhibitors, and our ongoing collaboration with Lilly, continues to validate our approach and strengthen our position in the industry. I'm particularly excited about what Nimbus will continue to discover and advance, as we leverage our computational drug discovery engine to bring innovative medicines for patients.” Bruce Booth, Chairman of the Board and co-founder of Nimbus, affirmed the Board’s unanimous support for Kazimi and acknowledged Keiper’s significant contributions to the company’s growth.
